Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-1110 in Social Anxiety Disorder
NCT06805565Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Social Anxiety Disorder (SAD) comparing ONO-1110 with Placebo (2 arms). Primary endpoint: Liebowitz Social Anxiety Scale Japanese version total score at 12 weeks. Started Jan 2025; status: completed.
02
Drugs
ONO-1110
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT06805565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06805565.